IL6 and neoplasm: For example, targeting CXCL12 could enhance the tumor growth-suppressing effect of PD-1/PD-L1.30 In addition, combined blockade of IL-6 and PD-1/PD-L1 could enhance the effective T cell infiltration into tumors.31 We recently showed that CCL-5 was upregulated by C-FOXP3 to recruit Treg cells into PDAC.12 Thus, PD-L1 could be a promising strategy to enhance the effect of CCL-5 antibody to treat PDAC, especially PDACs with high C-FOXP3 levels.